title: Feverish Quest for Ebola Immunotherapy: Straight or Cocktail?
abstract: The ebolavirus immunotherapeutics field has replaced previous perceptions of antibody inadequacy with a new abundance of monoclonals exhibiting post exposure efficacy. Now the questions are: what epitopes to target, what immunological mechanisms to seek, whether species-specific or broadly reactive antibodies are best, and whether a cocktail or monotherapy should be used.
authors.affiliation: Department of Immunology and Microbial Science, The Scripps Research Institute, La Jolla, CA, USA; Skaggs Institute for Chemical Biology, The Scripps Research Institute, La Jolla, CA, USA. Electronic address: erica@scripps.edu.
authors.forename: Erica Ollmann
authors.initials: EO
authors.lastname: Saphire
authors.affiliation: Integrated BioTherapeutics, Inc., Gaithersburg, MD, USA. Electronic address: javad@integratedbiotherapeutics.com.
authors.forename: M Javad
authors.initials: MJ
authors.lastname: Aman
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000276:immunology / Q000627:therapeutic use*; D057134:Antibodies, Neutralizing / Q000276:immunology / Q000627:therapeutic use*; D000914:Antibodies, Viral / Q000276:immunology / Q000627:therapeutic use*; D029043:Ebolavirus / Q000276:immunology*; D000939:Epitopes / Q000276:immunology; D019142:Hemorrhagic Fever, Ebola / Q000628:therapy* / Q000821:virology; D006801:Humans; D007167:Immunotherapy / Q000379:methods*; D051379:Mice; D014759:Viral Envelope Proteins / Q000276:immunology*
chemical_list: D000911:Antibodies, Monoclonal; D057134:Antibodies, Neutralizing; D000914:Antibodies, Viral; D000939:Epitopes; D014759:Viral Envelope Proteins; C113189:envelope glycoprotein, Ebola virus